Physician

Robert Lepine Fontane, M.D.

According to 2025 Medicare claims, Robert Fontane, M.D. (NPI: 1033140637) practices urology in the Alexandria, LA market, with the plurality of this provider's patient population coming from Rapides, LA. This provider's primary affiliated billing organization is CENLA UROLOGY CLINIC LLC (NPI: 1487879094; TIN: 720597185) and primary practice location at 71301-3917.

Fontane's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 897 traditional Medicare patients, billed 58,041 HCPCS/CPT codes, and received $353,299 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,359 prescription claims across 573 beneficiaries totaling $796,614 in drug costs, led by Xtandi (Enzalutamide). DME data shows 14 claims. Open Payments data shows 49 records totaling $1,014. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $180,020 to $796,614. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,077 to $294.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	928	21,601	$288,883
2016	1,221	25,559	$366,620
2017	1,389	27,507	$386,525
2018	1,256	22,225	$339,132
2019	1,132	21,663	$322,932
2020	1,394	43,925	$430,089
2021	1,489	73,614	$761,304
2022	1,326	79,832	$869,774
2023	1,292	46,330	$421,529
2024	897	58,041	$353,299

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	505	2,870	$180,020
2016	629	3,530	$166,516
2017	649	3,796	$182,675
2018	635	3,767	$180,497
2019	624	3,404	$149,872
2020	656	3,546	$252,868
2021	615	2,873	$564,339
2022	585	2,509	$582,170
2023	577	2,299	$474,757
2024	573	2,359	$796,614

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	48	$4,913
2016	N/R	41	$4,279
2017	N/R	65	$6,056
2018	N/R	19	$3,381
2019	N/R	64	$7,092
2020	N/R	66	$7,431
2021	N/R	113	$9,471
2022	N/R	56	$5,259
2023	N/R	N/R	N/R
2024	N/R	14	$4,396

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	442	699	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	198	223	$62
81007	Urinalysis for bacteria	168	194	$29
36415	Insertion of needle into vein for collection of blood sample	178	195	$9
81003	Automated urinalysis test	505	807	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	43	1,290	$618,793
Myrbetriq	Mirabegron	47	2,130	$31,472
Gemtesa	Vibegron	49	1,366	$21,824
Tamsulosin Hcl	Tamsulosin Hcl	664	42,165	$6,757
Finasteride	Finasteride	261	16,788	$3,373

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	14	$4,396

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	49	$1,014	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert Lepine Fontane, M.D.?

Tedicare shows public-source Medicare data for Robert Lepine Fontane, M.D. (NPI 1033140637), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert Lepine Fontane, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Robert Lepine Fontane, M.D.?

Robert Lepine Fontane, M.D. is linked to CENLA UROLOGY CLINIC LLC (billing NPI 1487879094) in the available physician profile data.

Does Robert Lepine Fontane, M.D. have Open Payments data?

Robert Lepine Fontane, M.D. has 49 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.